NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Cefovecin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Generic Name
Cefovecin
DrugBank Accession Number
DB11505
Background

Cefovecin is a cephalosporin antibiotic used for the treatment of skin infections in cats and dogs. It is the first single-dose injectable antibiotic for dogs and cats that assures owner compliance with dosing for the animal. It is used for the treatment of skin infections caused by Pasturella multocida in cats, and Staphylococcus intermedius/S. canis in dogs. The advantage of using injectable antibiotics is not missing a dose that can allow partially resistant microbes to recover during missed doses. However, these injectable agents can present long-lasting subtherapeutic concentrations after the resolution of infection. The presence of low concentrations of antibiotics is related to the development of microbial resistance.

Type
Small Molecule
Groups
Experimental, Vet approved
Structure
3D
Similar Structures
Weight
Average: 453.49
Monoisotopic: 453.0776757
Chemical Formula
C17H19N5O6S2
Synonyms
  • Cefovecin
Unlock the secrets to drugging the undruggable
Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.
Download eBook
Unlock the secrets to drugging the undruggable
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Cefovecin sodiumDL8Q24959P141195-77-9QRIBXVGHDLFNNE-VQWMGBAQSA-M

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
0D1OL46ZIE
CAS number
Not Available
InChI Key
ZJGQFXVQDVCVOK-QFKLAVHZSA-N
InChI
InChI=1S/C17H19N5O6S2/c1-27-21-10(8-6-30-17(18)19-8)13(23)20-11-14(24)22-12(16(25)26)7(5-29-15(11)22)9-3-2-4-28-9/h6,9,11,15H,2-5H2,1H3,(H2,18,19)(H,20,23)(H,25,26)/b21-10-/t9-,11+,15+/m0/s1
IUPAC Name
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-3-[(2S)-oxolan-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC([C@@H]3CCCO3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O

References

General References
  1. Stegemann MR, Sherington J, Coati N, Brown SA, Blanchflower S: Pharmacokinetics of cefovecin in cats. J Vet Pharmacol Ther. 2006 Dec;29(6):513-24. [Article]
  2. Stegemann MR, Sherington J, Blanchflower S: Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther. 2006 Dec;29(6):501-11. [Article]
  3. Thuesen LR, Bertelsen MF, Brimer L, Skaanild MT: Selected pharmacokinetic parameters for Cefovecin in hens and green iguanas. J Vet Pharmacol Ther. 2009 Dec;32(6):613-7. doi: 10.1111/j.1365-2885.2009.01083.x. [Article]
  4. Lawrence M, Kukanich K, Kukanich B, Heinrich E, Coetzee JF, Grauer G, Narayanan S: Effect of cefovecin on the fecal flora of healthy dogs. Vet J. 2013 Oct;198(1):259-66. doi: 10.1016/j.tvjl.2013.04.010. Epub 2013 May 20. [Article]
  5. Iyori K, Toyoda Y, Ide K, Iwasaki T, Nishifuji K: Usefulness of cefovecin disk-diffusion test for predicting mecA gene-containing strains of Staphylococcus pseudintermedius and clinical efficacy of cefovecin in dogs with superficial pyoderma. Vet Dermatol. 2013 Feb;24(1):162-7.e35-6. doi: 10.1111/j.1365-3164.2012.01100.x. [Article]
  6. Passmore CA, Sherington J, Stegemann MR: Efficacy and safety of cefovecin for the treatment of urinary tract infections in cats. J Small Anim Pract. 2008 Jun;49(6):295-301. doi: 10.1111/j.1748-5827.2008.00545.x. Epub 2008 Apr 14. [Article]
  7. Stegemann MR, Sherington J, Passmore C: The efficacy and safety of cefovecin in the treatment of feline abscesses and infected wounds. J Small Anim Pract. 2007 Dec;48(12):683-9. Epub 2007 Aug 23. [Article]
  8. Six R, Cherni J, Chesebrough R, Cleaver D, Lindeman CJ, Papp G, Skogerboe TL, Weigel DJ, Boucher JF, Stegemann MR: Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. J Am Vet Med Assoc. 2008 Aug 1;233(3):433-9. doi: 10.2460/javma.233.3.433. [Article]
  9. Stegemann MR, Coati N, Passmore CA, Sherington J: Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. J Small Anim Pract. 2007 Jul;48(7):378-86. Epub 2007 Jun 9. [Article]
  10. Passmore CA, Sherington J, Stegemann MR: Efficacy and safety of cefovecin (Convenia) for the treatment of urinary tract infections in dogs. J Small Anim Pract. 2007 Mar;48(3):139-44. [Article]
ChemSpider
4891661
RxNav
1591901
ChEMBL
CHEMBL2110625
ZINC
ZINC000004654838
Wikipedia
Cefovecin

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.182 mg/mLALOGPS
logP0.46ALOGPS
logP-0.77Chemaxon
logS-3.4ALOGPS
pKa (Strongest Acidic)2.8Chemaxon
pKa (Strongest Basic)3.62Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count9Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area156.44 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity107.92 m3·mol-1Chemaxon
Polarizability43.05 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0040900000-6697538c040c95e564ae
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-1290000000-6e9c6c439cb38c256f1e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ik9-0190300000-b9aef1297f561cb5a2fe
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-05vo-1265900000-fb827cfc071ed6648ca3
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03k9-0392600000-be88cb8bce8784f89024
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00fr-1900000000-065481a73b2830ead11c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at February 26, 2016 17:26 / Updated at February 21, 2021 18:53